Select Language
Free Registration
My Cart

HLA-C*07:02:01 & B2M & RYR

Product Inquiry

HLA-C*07:02:01 & B2M & RYR Background

HLA-A, B, and C are transmembrane glycoproteins in the major histocompatibility complex 1 (MHC I) family. The C receptor is a heterodimer consisting of a HLA-C mature gene product (heavy chain) and β2-microglobulin (light chain). The mature C chain is anchored in the membrane. HLA class I molecules play a central role in the immune system by presenting peptides derived from endoplasmic reticulum lumen. HLA-C are expressed in nearly all cells, and present small peptides to the immune system which surveys for non-self peptides.Biotinylated Human HLA-C*07:02:01&B2M&RYR (RYRPGTVAL) Complex Protein is a complex of HLA-C*07:02:01 of the MHC Class I, B2M and RMFPNAPYL peptide of the RYR.

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
Recombinant humanized anti-IL-6R antibody (Hisun Pharma)HS-628Phase 3 ClinicalZhejiang Hisun Pharmaceutical Co LtdArthritis, Rheumatoid; Arthritis
Details
VDJ-001Phase 3 ClinicalBeijing Vdjbio Co LtdArthritis, Rheumatoid; Multicentric Castleman's Disease (MCD)
Details
Tocilizumab biosimilar (AryoGen Pharmed)Phase 3 ClinicalAryogen BiopharmaArthritis, Rheumatoid
Details
CMAB806CMAB-806Phase 3 ClinicalTaizhou Maibo Taike Biotechnology Co LtdArthritis, Rheumatoid; Arthritis
Details
LevilimabBCD-089Phase 3 ClinicalBiocadArthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19)
Details
OlamkiceptFE-999301; CR-5/18; TJ-301; FE-301Phase 2 ClinicalConaris Research InstituteGastrointestinal Diseases; Colitis, Ulcerative
Details
Atexakin alfaSON-080; r-IL-6Phase 2 ClinicalWeizmann Institute Of SciencePeripheral Nervous System Diseases; Diabetic Neuropathies
Details
Tocilizumab Biosimilar (qyuns)QX-003-SPhase 1 ClinicalQyuns Therapeutics Co LtdArthritis, Rheumatoid
Details
Tocilizumab Biosimilar (Destiny)IA-001; IA001Phase 1 ClinicalShanghai Destiny Biotech Co LtdPolyarticular Juvenile Idiopathic Arthritis; Arthritis, Rheumatoid
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyEarliest Brand NameEarliest Approval CountryEarliest IndicationEarliest Approval CompanyEarliest Approval DateIndicationClinical Trial
TocilizumabrhPM-1; RO-48775533; RG-1569; MRA; HPM-1; MRA-SC; R-1569ApprovedChugai Pharmaceutical Co LtdActemra, RoActemra, 雅美罗, Actemra/RoActemra, ActermaJapanArthritis, Juvenile; Arthritis, Rheumatoid; Giant Cell Arteritis; Takayasu Arteritis; Cytokine Release Syndrome; Multicentric Castleman's Disease (MCD)null2005-04-11Lymphoma; Graves Ophthalmopathy; Ascites; Takayasu Arteritis; Pancreatitis, Chronic; Coronavirus Infections; Pulmonary Arterial Hypertension; Coronary Disease; Lupus Erythematosus, Systemic; Breast Neoplasms; systemic sclerosis-associated interstitial lung disease; Multicentric Castleman's Disease (MCD); Fever; Uveitis, Posterior; Stroke; Pulmonary Disease, Chronic Obstructive; Osteoarthritis; Uveitis; Rejection in heart transplantation; Inflammation; Pleural Effusion, Malignant; Panuveitis; Diabetes Mellitus; Behcet Syndrome; Amyotrophic Lateral Sclerosis; Anemia, Sickle Cell; Carcinoma, Hepatocellular; Non-ST Elevated Myocardial Infarction; Myocardial Infarction; Hematologic Neoplasms; Solid tumours; Cytokine Release Syndrome; Motor Neuron Disease; HIV Infections; Diabetes Mellitus, Type 1; Acute Chest Syndrome; Craniopharyngioma; Polymyositis; Giant Cell Arteritis; Schnitzler Syndrome; Depressive Disorder, Major; Polyarticular Juvenile Idiopathic Arthritis; Non-radiographic axial spondyloarthritis; Uveitis
Details
Tocilizumab biosimilar (Bio-Thera Solutions)BAT-1806; BIIB-800ApprovedBio-Thera Solutions Ltd施瑞立, TOFIDENCEMainland ChinaArthritis, Rheumatoid; Arthritis, Juvenile; Cytokine Release SyndromeBio-Thera Solutions Ltd2023-01-16Cytokine Release Syndrome; Polyarticular Juvenile Idiopathic Arthritis; Arthritis, Rheumatoid; Arthritis, Juvenile
Details
SarilumabSAR-153191; REGN-88ApprovedSanofiKevzaraUnited StatesArthritis, RheumatoidSanofi-Synthelabo2017-05-22Non-radiographic axial spondyloarthritis; Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19); Sarcoidosis; Mastocytosis, Systemic; Arthritis, Juvenile; Polymyalgia Rheumatica; Severe Acute Respiratory Syndrome; Uveitis
Details
Tocilizumab biosimilar (Livzon Group)LZM-008ApprovedLivzon Pharmaceutical Group Inc安维泰Mainland ChinaArthritis, RheumatoidLivzon Mabpharm Inc2023-01-18Arthritis, Rheumatoid
Details
Tocilizumab biosimilar (Fresenius kabi)MSB-11456ApprovedMerck SeronoTyenne®EUCytokine Release Syndrome; Arthritis, Rheumatoid; Giant Cell Arteritis; Coronavirus Disease 2019 (COVID-19)Fresenius Kabi Deutschland Gmbh2023-09-15Cytokine Release Syndrome; Giant Cell Arteritis; Polyarticular Juvenile Idiopathic Arthritis; Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19)
Details
  • Product Inquiry
  • Marketed Drug Information
  • Clinical Drug Information
Share to:

Join UsLegalSite MapPrivacy PolicyTerms and Conditions
Website Feedback
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

order@acrobiosystems.com

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland